Rapamycin reduced fatty plaque buildup in arteries by more than half and increased immune cells’ ability to clear dead tissue from plaques nearly 4-fold in mice with atherosclerosis, according to a 2026 research study. The drug works by protecting immune cells from ferroptosis, a type of damage that harms the energy-producing centers of cells. While these laboratory and animal results are promising, human clinical trials are needed before rapamycin could become a heart disease treatment.
Researchers discovered that a drug called rapamycin may help protect heart cells from damage and improve how the body clears away dead cells in artery plaques. According to Gram Research analysis, the study found that rapamycin reduced fatty buildup in arteries by nearly half in mice with atherosclerosis. The drug works by stopping a harmful process called ferroptosis, which damages the mitochondria (the energy centers of cells) and prevents immune cells from cleaning up dead tissue. This finding could lead to new treatments for heart disease, one of the leading causes of death worldwide.
Key Statistics
A 2026 research study found that rapamycin increased the plaque efferocytosis index from 0.36 to 1.37 in mice with atherosclerosis, nearly a 4-fold improvement in immune cells’ ability to clear dead tissue from artery plaques.
Rapamycin treatment reduced whole-aorta lipid-positive area from 25.32% to 12.28% in mice fed a high-fat diet for 12 weeks, cutting fatty plaque buildup by more than half after just 4 weeks of drug treatment.
In laboratory experiments with human immune cells, the drug FIN-56 reduced energy production and impaired cell function, but rapamycin partially reversed these ferroptosis-related abnormalities.
Ferroptosis-associated mitochondrial oxidative stress contributed to impaired immune cell function in atherosclerosis, as demonstrated by rescue experiments using MitoTEMPO in a 2026 study published in International Immunopharmacology.
The Quick Take
- What they studied: Whether a drug called rapamycin can help immune cells work better by protecting them from a type of damage called ferroptosis, which harms the energy-producing parts of cells.
- Who participated: Laboratory experiments used human immune cells grown in dishes and mice genetically modified to develop heart disease. The mouse study included 12 animals total (6 per group) fed a high-fat diet for 12 weeks before treatment.
- Key finding: Rapamycin increased the ability of immune cells to clean up dead tissue in plaques by nearly 4 times (from 0.36 to 1.37) and cut fatty plaque buildup in arteries by more than half (from 25% to 12%).
- What it means for you: This research is early-stage laboratory work, not yet tested in humans. If future human studies confirm these results, rapamycin might become a new treatment option for heart disease by helping the body naturally clear dangerous plaque from arteries.
The Research Details
This study combined laboratory experiments with animal testing. Researchers first grew human immune cells called macrophages in dishes and exposed them to a chemical that triggers ferroptosis, a type of cell damage. They then treated these cells with rapamycin to see if it could protect them and restore their ability to clean up dead cells. To confirm their findings, they tested rapamycin in mice that were genetically prone to developing atherosclerosis (clogged arteries). The mice ate a high-fat diet for 12 weeks to develop plaque buildup, then received either rapamycin or a placebo treatment twice weekly for 4 weeks. Researchers measured changes in plaque size, cell damage markers, and immune cell function throughout the study.
This research approach is important because it bridges laboratory discovery with real-world disease. Testing in both cells and animals helps researchers understand how a drug works at the molecular level while also seeing if those benefits translate to actual disease improvement. This two-step approach gives scientists confidence that promising lab results might eventually help human patients.
The study used multiple methods to measure outcomes, including genetic analysis and direct measurement of cell function. The researchers used control groups and pharmacological tools to confirm that ferroptosis and mitochondrial damage were actually responsible for the problems they observed. However, this is early-stage research conducted only in laboratory settings and mice, not humans. Results in animals do not always translate to humans, so much more testing would be needed before this could become a medical treatment.
What the Results Show
When researchers exposed immune cells to ferroptosis-triggering chemicals, the cells showed multiple signs of damage: increased fatty buildup inside cells, reduced energy production, and weakened ability to clean up dead tissue. Rapamycin treatment partially reversed this damage. The drug reduced harmful oxidative stress in the mitochondria and restored some of the cells’ cleaning ability. In mice with atherosclerosis, rapamycin treatment produced even more dramatic results. The drug increased the immune cells’ ability to clear dead tissue from plaques nearly 4-fold and reduced the total fatty plaque area in arteries by more than half. These improvements occurred after just 4 weeks of treatment.
The study identified specific proteins that were damaged during ferroptosis, including MERTK and MFG-E8, which are crucial for immune cells to recognize and clean up dead tissue. Rapamycin helped restore these proteins. The researchers also found that mitochondrial damage, specifically oxidative stress within these energy centers, was a major contributor to the immune cells’ inability to function properly. When they used other drugs to specifically target mitochondrial damage, they saw improvements in cell cleaning ability, confirming this mechanism.
Previous research had shown that ferroptosis and mitochondrial dysfunction occur in atherosclerosis, but this is among the first studies to directly link these processes to impaired immune cell function in plaque. The finding that rapamycin can address both ferroptosis and mitochondrial damage is novel. Rapamycin has been studied for decades in various diseases, but its specific role in protecting immune cells during atherosclerosis represents a new application for this existing drug.
This research was conducted entirely in laboratory dishes and mice, not in humans. Mice do not always respond to treatments the same way humans do. The study used relatively small sample sizes (12 mice total, 3 biological replicates in cell studies). The treatment period was short (4 weeks in mice), so long-term effects remain unknown. The study did not examine potential side effects of rapamycin, which is an immunosuppressant drug that can have serious consequences with long-term use. Human clinical trials would be necessary to determine if these results are safe and effective in people.
The Bottom Line
This research provides moderate evidence that rapamycin may help protect immune cells in atherosclerosis through laboratory and animal studies. However, it is too early to recommend rapamycin for heart disease prevention or treatment in humans. Anyone currently taking rapamycin for other conditions should not change their treatment based on this research. Future human clinical trials are needed to determine safety and effectiveness.
This research is most relevant to cardiologists, immunologists, and pharmaceutical researchers developing new heart disease treatments. People with atherosclerosis or family history of heart disease should be aware of this emerging research but should not expect immediate clinical applications. This work may eventually benefit millions of people with heart disease, but that is years away.
This is fundamental research, not a treatment ready for patients. Typically, promising laboratory findings take 10 to 15 years to become available medical treatments. Researchers would need to conduct safety studies, then small human trials, then larger clinical trials before any potential approval. Realistic timeline for human use: 10 to 20 years if development continues successfully.
Frequently Asked Questions
What is ferroptosis and why does it matter for heart disease?
Ferroptosis is a type of cell death involving iron and fat damage that harms immune cells in artery plaques. When immune cells die from ferroptosis, they cannot clean up dead tissue, allowing dangerous plaque to accumulate. This 2026 study shows rapamycin may prevent ferroptosis and restore immune cell function.
Can I take rapamycin now to prevent heart disease?
No. Rapamycin is currently approved only for specific medical uses like preventing organ rejection after transplants. This research is early-stage and has only been tested in mice. Human clinical trials are required before any new heart disease treatment could be approved for patients.
How long until this research leads to a new heart disease treatment?
Typically 10 to 20 years from promising laboratory findings to approved medical treatment. Researchers must conduct safety studies, then small and large human trials. If development continues successfully, rapamycin-based therapies might eventually help heart disease patients, but that timeline is uncertain.
Does this mean my mitochondria are damaged if I have heart disease?
Mitochondrial dysfunction occurs in atherosclerosis, but this research shows it is one of several contributing factors. Having heart disease risk does not automatically mean your mitochondria are severely damaged. Talk to your doctor about your individual risk factors and prevention strategies.
What can I do now to protect my immune cells and heart health?
Exercise regularly (150 minutes weekly), eat a heart-healthy diet low in saturated fat, maintain a healthy weight, manage stress, and avoid smoking. These proven strategies improve immune function and reduce plaque buildup. Regular checkups help monitor your cardiovascular health.
Want to Apply This Research?
- Users interested in heart health could track weekly cholesterol levels, blood pressure readings, and arterial stiffness measurements (if available through their healthcare provider) to monitor cardiovascular risk factors that this research might eventually address.
- While rapamycin is not yet available as a heart disease treatment, users can adopt evidence-based practices now: reduce saturated fat intake, increase aerobic exercise to 150 minutes weekly, maintain healthy weight, and manage stress. These actions improve immune cell function and reduce plaque buildup through proven mechanisms.
- Set up monthly reminders to log cardiovascular health markers including blood pressure, resting heart rate, and dietary adherence. Track any new research updates on ferroptosis and atherosclerosis treatments. Share results with healthcare providers to identify personalized risk reduction strategies while waiting for potential future treatments based on this research.
This article summarizes early-stage laboratory and animal research that has not been tested in humans. Rapamycin is not approved for heart disease treatment and should only be used under medical supervision for its currently approved indications. Do not start, stop, or change any medications based on this research. Consult your healthcare provider about your individual heart disease risk and appropriate prevention or treatment strategies. Animal studies do not always produce the same results in humans, and many years of additional research would be needed before any potential clinical application.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.